In a systematic review and network meta-analysis, Zhang et al
(9) Further, preliminary research involving CJC-1295 (Mod GRF 1-29) 1-29 indicates a potential rise in nocturnal growth hormone levels, as well as serum levels of IGF-I and IGFBP-3, and GHBP concentrations
We review history, medications, BMI, and order labs to determine candidacy
Lifestyle and routine play a significant role in adherence
Agents such as oral semaglutide, orforglipron, CagriSema, retatrutide and maridebart cafraglutide have achieved unprecedented mean weight reductions, often exceeding 15% to 20% of baseline body weight in clinical trials.37 Clinicians must keep in mind that pharmacotherapy alone is not a cure for obesity
Caution Always use under medical supervision to avoid potential side effects such as edema, joint pain, or more severe allergic reactions